{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Thompson P"],"funding":["NCI NIH HHS","NIGMS NIH HHS"],"pagination":["831-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4282931"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["74(4)"],"pubmed_abstract":["<h4>Purpose</h4>We explored the impact of obesity, body composition, and genetic polymorphisms on the pharmacokinetics (PK) of daunorubicin in children with cancer.<h4>Patients and methods</h4>Patients ≤21 years receiving daunorubicin as an infusion of any duration <24 h for any type of cancer were eligible. Plasma drug concentrations were measured by high-performance liquid chromatography. Body composition was measured by dual-energy X-ray absorptiometry. Obesity was defined as a BMI >95% for age or as body fat >30%. NONMEM was used to perform PK model fitting. The Affymetrix DMET chip was used for genotyping. The impact of genetic polymorphisms was investigated using SNP/haplotype association analysis with estimated individual PK parameters.<h4>Results</h4>A total of 107 subjects were en"],"journal":["Cancer chemotherapy and pharmacology"],"pubmed_title":["Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group."],"pmcid":["PMC4282931"],"funding_grant_id":["U10 CA098543","UG1 CA189955","GM61393","U10 CA180886","U01 GM061393","F32CA165823","F32 CA165823","U10 CA180899","U10 CA095861","U10 CA098413"],"pubmed_authors":["Devidas M","Sung L","Dolan ME","Thompson P","Lorier R","Delaney SM","Wheeler HE","Broeckel U","Berg SL","Reaman GH","Scorsone K"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.","description":"<h4>Purpose</h4>We explored the impact of obesity, body composition, and genetic polymorphisms on the pharmacokinetics (PK) of daunorubicin in children with cancer.<h4>Patients and methods</h4>Patients ≤21 years receiving daunorubicin as an infusion of any duration <24 h for any type of cancer were eligible. Plasma drug concentrations were measured by high-performance liquid chromatography. Body composition was measured by dual-energy X-ray absorptiometry. Obesity was defined as a BMI >95% for age or as body fat >30%. NONMEM was used to perform PK model fitting. The Affymetrix DMET chip was used for genotyping. The impact of genetic polymorphisms was investigated using SNP/haplotype association analysis with estimated individual PK parameters.<h4>Results</h4>A total of 107 subjects were en","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Oct","modification":"2026-04-29T12:13:32.095Z","creation":"2019-03-27T01:42:40Z"},"accession":"S-EPMC4282931","cross_references":{"pubmed":["25119182"],"doi":["10.1007/s00280-014-2535-4"]}}